{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:44:53Z","timestamp":1760550293146,"version":"build-2065373602"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,2,18]],"date-time":"2018-02-18T00:00:00Z","timestamp":1518912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate willingness to pay (<jats:styled-content style=\"fixed-case\">WTP<\/jats:styled-content>) for treatment with infliximab by patients with ankylosing spondylitis (<jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content>) and explore factors associated with <jats:styled-content style=\"fixed-case\">WTP<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from 85 patients participating in the European <jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content> Infliximab Cohort (<jats:styled-content style=\"fixed-case\">EASIC<\/jats:styled-content>) open\u2010label extension of the <jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content> Study for the Evaluation of Recombinant Infliximab Therapy (<jats:styled-content style=\"fixed-case\">ASSERT<\/jats:styled-content>) were used. <jats:styled-content style=\"fixed-case\">WTP<\/jats:styled-content> was included at baseline in <jats:styled-content style=\"fixed-case\">EASIC<\/jats:styled-content> and comprised a hypothetical scenario exploring whether the patient would be willing to pay for beneficial effects of infliximab and, if so, what amount they would be willing to pay per administration. Factors associated with <jats:styled-content style=\"fixed-case\">WTP<\/jats:styled-content> were explored using zero\u2010inflated negative binomial (<jats:styled-content style=\"fixed-case\">ZINB<\/jats:styled-content>) regressions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 85 patients, 63 (74.1%) were willing to pay, and among these, the mean amount they were willing to pay per administration was \u20ac275 (median \u20ac100 [interquartile range \u20ac50\u2013200]). Multivariable <jats:styled-content style=\"fixed-case\">ZINB<\/jats:styled-content> analysis showed that Assessment of SpondyloArthritis international Society criteria for 20% improvement (<jats:styled-content style=\"fixed-case\">ASAS<\/jats:styled-content>20) response was associated with a 7\u2010fold lower likelihood to pay 0 euros (odds ratio [<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>] 0.14 [95% confidence interval (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>) 0.03\u20130.71]) and a 3\u2010fold increase in the amount willing to pay (exp(\u03b2) = 3.32 [95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 1.44\u20137.69]). In addition, the country of residence was associated with a lower likelihood to pay 0 euros (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content> 0.07 [95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.02\u20130.36]), while increased age was associated with the amount willing to pay (exp(\u03b2) = 1.05 [95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 1.01\u20131.09]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In a hypothetical scenario, three\u2010quarters of patients with <jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content> receiving long\u2010term infliximab stated that they were willing to pay an out\u2010of\u2010pocket contribution for this treatment. Treatment response contributed to the willingness as well as to the amount patients were willing to pay.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.23299","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T12:42:45Z","timestamp":1496407365000},"page":"608-616","source":"Crossref","is-referenced-by-count":1,"title":["Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness\u2010to\u2010Pay Approach"],"prefix":"10.1002","volume":"70","author":[{"given":"Casper","family":"Webers","sequence":"first","affiliation":[{"name":"Maastricht University Medical Center and School for Public Health and Primary Care (CAPHRI) Maastricht University Maastricht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivette","family":"Essers","sequence":"additional","affiliation":[{"name":"Maastricht University Medical Center and School for Public Health and Primary Care (CAPHRI) Maastricht University Maastricht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"van Tubergen","sequence":"additional","affiliation":[{"name":"Maastricht University Medical Center and School for Public Health and Primary Care (CAPHRI) Maastricht University Maastricht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Braun","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet Herne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Heldmann","sequence":"additional","affiliation":[{"name":"Zeisigwaldkliniken Bethanien Chemnitz Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet Herne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[{"name":"Maastricht University Medical Center and School for Public Health and Primary Care (CAPHRI) Maastricht University Maastricht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh584"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.075879"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20852"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201914"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3182514093"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200523030-00008"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1050(199806)7:4<313::AID-HEC350>3.0.CO;2-B"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8510(99)00010-X"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X9601600314"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725020-00004"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.7.791"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1280-1"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X08315252"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.10.005"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.038786"},{"key":"e_1_2_7_19_1","first-page":"672","article-title":"The European Ankylosing Spondylitis Infliximab Cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab","volume":"29","author":"Heldmann F","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"e_1_2_7_21_1","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_7_22_1","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin A","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.1.66"},{"key":"e_1_2_7_24_1","first-page":"1694","article-title":"Defining spinal mobility in ankylosing spondylitis (AS): The Bath AS Metrology Index","volume":"21","author":"Jenkinson TR","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016717"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200220040-00004"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X9601600309"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.76.4.392"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(96)00300-0"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.11.1242"},{"key":"e_1_2_7_32_1","first-page":"443","article-title":"Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspective","volume":"32","author":"Fautrel B","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/0049124103262689"},{"key":"e_1_2_7_34_1","unstructured":"World Health Organization.Global health expenditure database (2016). URL:http:\/\/apps.who.int\/nha\/database."},{"volume-title":"Healthcare systems: The Netherlands","year":"2013","author":"Daley C","key":"e_1_2_7_35_1"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200422110-00001"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.23299","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.23299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:08:41Z","timestamp":1759417721000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.23299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,18]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1002\/acr.23299"],"URL":"https:\/\/doi.org\/10.1002\/acr.23299","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"type":"print","value":"2151-464X"},{"type":"electronic","value":"2151-4658"}],"subject":[],"published":{"date-parts":[[2018,2,18]]}}}